THERAPEUTIC APPLICATION OF DIMIRACETAM FOR PREVENTION OF A PALM SUSPENSION SYNDROME CAUSED BY SORAFENIB

摘要

1. The use of dimiracetam or its solvate in the treatment and / or prevention of allodynia, in particular, allodynia of the hands and / or feet induced by sorafenib. The use according to claim 1, wherein sorafenib is administered or has been administered in combination therapy with other antitumor chemotherapeutic agents. The use according to claim 1, in which one sorafenib is administered, i.e. in the absence of other antitumor chemotherapeutic agents. 4. The use of dimiracetam or its solvate in combination with sorafenib and, optionally, with one or more other antitumor chemotherapeutic agents in the treatment of cancer. 5. The use according to any one of claims 1 or 4, in which dimiracetam is in the form of a mixture of (S) - and (R) enantiomer. The use according to any one of claims 1 or 4 at a dose for daily oral administration of from about 1 to about 100 mg / kg, preferably from about 8 to about 70 mg / kg, in particular from about 5 to about 65 mg / kg , or in a dose for daily intramuscular administration of from about 5 to about 25 mg / kg, in particular from about 8 to about 20 mg / kg, or in a dose for daily intravenous administration of from about 2 to about 20 mg / kg in particular from 5 to 20 mg / kg, or in a dose for daily rectal administration of about 8 d about 70 mg / kg, preferably 10 to 65 mg / kg, in particular 5 to 35 mg / kg. The use according to any one of claims 1 or 4 in a dose for daily administration, including blood levels of 100-500 micromolar. The use according to any one of claims 1 or 4 in the form of a medicament suitable for daily pro-Kg administration of an amount of dimiracetam orally: approximately